Welcome Guest  |  Register/Login  | 
Email: sales@marketreportsonline.com Call : + 1 888 391 5441
SEARCH:   

Indonesia Pharmaceuticals and Healthcare Report Q3 2012

Published : 
No. of Pages : 103
  Buy Now  

BMI View: The government’s aim to create proper universal healthcare coverage is unlikely to be realised in the short term but would create investors’ interest in the country. We highlight some of the beneficiaries such as local generic drug manufacturers and medical devices suppliers. Given the country’s low per capita pharmaceutical and healthcare expenditure, it presents significant opportunities for drugmakers over the long term as an expected improvement in its economy will help to boost spending on healthcare.
Headline Expenditure Projections 􀂃 Pharmaceuticals: IDR53,041bn (US$6.04bn) in 2011 to IDR58,727bn (US$6.38bn) in 2012; +10.7% growth in local currency terms and +5.6% in US dollar terms. Growth rates broadly unchanged from previous quarter.
􀂃 Healthcare: IDR193,6010bn (US$22.06bn) in 2011 to IDR221,373bn (US$24.06bn) in 2012; +14.3% growth in local currency terms and +9.1% in US dollar terms. Growth forecast upgraded due to receipt of new historic data.
􀂃 Medical devices: IDR5,721bn (US$652mn) in 2011 to IDR6,294bn (US$684mn) in 2012; +10.0% growth in local currency terms and +5.0% in US dollar terms. Growth forecast upgraded but absolute numbers were readjusted downwards due to new historic trade figures.
Risk/Reward Rating: Indonesia is ranked 11th out of the 18 Asia Pacific markets in BMI’s Q312 Pharmaceutical and Healthcare Risk/Reward Ratings (RRRs). This is a rise from 13th in Q212 as there was an improvement to its Industry Rewards score and declines in the same category for Thailand and the Philippines, bringing their overall rating downwards.
Key Trends And Developments 􀂃 In May 2012, Pfizer Indonesia director Widyaretna Buenastuti told the Jakarta Post the company intends to expand in the generic drug market in Indonesia and increase its market share. The company will invest US$3mn to expand its factory capacity. Pfizer Indonesia is in discussions with the National Agency of Drug and Food Control/Badan Pengawas Obat dan Makanan (NADFC/BPOM) to implement its plan by the end of 2012. The company is seeking expansion ahead of the introduction of the government’s social security system to roll out more health insurance.
􀂃 In March 2012, Kimia Farma signed an agreement with Prakarsa Transforma Indonesia to establish a subsidiary called Kimia Farma Hospital. Kimia Farma will own a 60% stake in the new commercial entity. The first hospital is expected to be completed by the end of 2013 and the subsidiary will build at least five more.
􀂃 In the same month, Bio Farma said it will be ready to launch a pentavalent vaccine at the end of 2012 to meet domestic and foreign demand. This will make Indonesia the world’s fifth pentavalent vaccine producer. Pentavalent is a combination of five different vaccines for diphtheria, pertussis, tetanus, hepatitis B and haemophilus influenza type B (HIB). The other pentavalent vaccine producing countries are the US, India, Belgium and France.
BMI Economic View: With Bank Indonesia increasingly likely to reverse its easing campaign by hiking interest rates in lieu of rising price pressure, we expect the investment climate in Indonesia to deteriorate over the coming quarters, and in turn have cut our fixed capital growth outlook from 8.5% to 7.5% for 2012. Likewise, we forecast a slightly weaker outlook for the consumer taking its toll on private consumption, for which we have also downgraded our forecast to 4.5% from 5.3%. In line with these downgrades, we now see the Indonesian economy growing by 5.4% in 2012, compared to our previous forecast of 5.8%.
BMI Political View: The growing trend of official placation of hardline religious groups threatens Indonesia’s long-term attempts to foster a religiously pluralistic society, along with stated goals of separating religion and state. Furthermore, the fact that a few Islamist groups, including the Islamic Defenders Front and Indonesian Mujahedeen Council, seem to have disproportionate power with law enforcement and with parts of the government bodes poorly for the diverse country’s characteristics of polity and could lead to social unrest in the long-term.

CONTENTS 3
SWOT Analysis . 7
Indonesia Pharmaceutical And Healthcare Industry SWOT 7
Indonesia Political SWOT 8
Indonesia Economic SWOT 9
Indonesia Business Environment SWOT . 10
Pharmaceutical Risk/Reward Ratings 11
Table: Asia Pacific Pharmaceutical And Healthcare Risk/Reward Ratings, Q312 . 11
Rewards 12
Risks 13
Market Summary – Indonesia 14
Regulatory Regime . 15
Pharmaceutical Advertising 16
Regional Harmonisation 17
Intellectual Property Issues 18
Counterfeit Drugs . 19
Generic Drug Legislation 21
Labelling Requirements 21
Free Trade Agreements. 22
Pricing Regime 23
Reimbursement Regime . 24
Industry Trends And Developments 25
Epidemiology . 25
Non-Communicable Diseases 26
Communicable Diseases 27
Public Health Developments . 28
Table: UN Millennium Development Goals For Indonesia 29
Healthcare System 30
Health Insurance 32
Healthcare System Reform 33
Research & Development 35
Herbal Medicines 36
Medical Devices 37
Industry Forecast Scenario 38
Overall Market Forecast 38
Table: Pharmaceutical Sales, 2008-2016 . 39
Healthcare Market Forecast . 40
Table: Overall Healthcare Expenditure, 2008-2016 . 42
Table: Government Healthcare Expenditure, 2008-2016 . 43
Table: Private Healthcare Expenditure, 2008-2016 . 43
Key Growth Factors – Macroeconomic 44
Table: Indonesia Economic Activity, 2011-2016 . 48
Prescription Drug Market Forecast . 49
Table: Prescription Drug Sales, 2008-2016 50
Patented Drug Market Forecast . 51
Table: Patented Drug Sales, 2008-2016 . 52
Generic Drug Market Forecast 53
Table: Generic Drug Sales, 2008-2016 55
OTC Medicine Market Forecast . 56
Table: OTC Medicine Sales, 2008-2016 . 57
Medical Device Market Forecast 58
Table: Medical Device Sales, 2008-2016 59
Pharmaceutical Trade Forecast . 60
Table: Pharmaceutical Trade, 2008-2016 63
Other Healthcare Data And Forecasts 64
Key Risks To BMI’s Forecast Scenario 64
Competitive Landscape . 66
Table: Top-10 Pharmaceutical Companies According To Market Capitalisation 67
Domestic Industry . 67
Foreign Industry . 69
Recent Pharmaceutical Sector Developments 69
Pharmaceutical Retail Sector 70
Company Profiles 72
Soho Group . 72
PT Kalbe Farma . 74
PT Bio Farma 76
Kimia Farma 78
Combiphar PT . 81
Sanofi . 83
Pfizer . 85
Novartis 87
GlaxoSmithKline . 89
Merck & Co 91
Bayer . 93
Demographic Outlook . 95
Table: Population By Age Group, 1990-2020 (‘000) 96
Table: Population By Age Group, 1990-2020 (% of total) 97
Table: Key Population Ratios, 1990-2020 98
Table: Rural/Urban Population Split, 1990-2020 98
BMI Methodology 99
How We Generate Our Pharmaceutical Industry Forecasts 99
Pharmaceutical Risk/Reward Ratings Methodology 100
Ratings Overview .100
Table: Pharmaceutical Business Environment Indicators 101
Weighting 102
Table: Weighting Of Components 102
Sources 102Table: Asia Pacific Pharmaceutical And Healthcare Risk/Reward Ratings, Q312 . 11


Table: UN Millennium Development Goals For Indonesia . 29


Table: Pharmaceutical Sales, 2008-2016 . 39


Table: Overall Healthcare Expenditure, 2008-2016 . 42


Table: Government Healthcare Expenditure, 2008-2016 . 43


Table: Private Healthcare Expenditure, 2008-2016 . 43


Table: Indonesia Economic Activity, 2011-2016 . 48


Table: Prescription Drug Sales, 2008-2016 . 50


Table: Patented Drug Sales, 2008-2016 . 52


Table: Generic Drug Sales, 2008-2016 . 55


Table: OTC Medicine Sales, 2008-2016 . 57


Table: Medical Device Sales, 2008-2016 . 59


Table: Pharmaceutical Trade, 2008-2016 . 63


Table: Top-10 Pharmaceutical Companies According To Market Capitalisation . 67


Table: Population By Age Group, 1990-2020 (‘000) . 96


Table: Population By Age Group, 1990-2020 (% of total) . 97


Table: Key Population Ratios, 1990-2020 . 98


Table: Rural/Urban Population Split, 1990-2020 . 98


Table: Pharmaceutical Business Environment Indicators .101


Table: Weighting Of Components .102

Indonesia Pharmaceuticals and Healthcare Report Q3 2012

Published By: Business Monitor International
 

How to Purchase


Purchase products from our site in 5 easy steps.  Please follow the description given below to complete your purchase process.

Step 1:

Select the report title of your interest, and Click on Buy Now button next to the Price option.

Step 2:

You will arrive at the Purchase page, where you will be requested to Signup (New User) or Login (Registered User). Please note that in-keeping with the security check on the website, you must submit your full details to avoid any inconvenience arising from incorrectly entered data or counterfeit information.

Step 3:

After SignUp/Login, you will arrive at the Online Invoice Page. Select a Payment option via various methods: Debit Card / Credit Card / by Invoice. MarketReportOnline accepts Visa, MasterCard, American Express and all major credit cards. MarketReportOnline uses ICICI, HDFC, Citibank, American Express & Paypal as our Online Payment Gateway Partners. Clicking on a payment option will take you to the corresponding Payment Gateway page.

Step 4:

Once at the Payment Gateway, please complete the Payment Process to purchase your desired report.

Step 5:

Once you have successfully completed the purchase process, you will receive a confirmation email. You will then either be able to download your report immediately (in PDF Format) from the Account Login button, or the report will be emailed to you directly, depending upon the agreement we have with the publisher. For Orders that are deliverable via email and placed after working hours, the delivery of the reports will be made on the next business day. Please note, if you select purchase by invoice, you will receive your report only once the payment has been received. If you have any queries about how to order, please Contact Us .


Using our subscription option, you get access to market research reports and industry data of Industry Profiles market as per your needs. Get the best of Industry Profiles research reports by utilizing your research budgets in an optimum way.
More about our Subscription option
Get Email alerts about market research reports from industries and publishers of your interest:
© 2009 Market Research Reports. All Rights Reserved. Privacy Policy. Terms & Conditions